Every now and again, one of the members asks about taking bromocriptine vaginally.
In recent history, no one has posted about their experiences. I think that if you are having the really bad side effects, it's worth a try.
Vaginal Dopamine Agonists: Biochemical and Clinical Responses - A New Trial
Diaa El-Mowafi(1)*, Mamdouh Youssef(2) and Mona A. Hassan(3
Obstetrics and Gynecology(1), Medical Biochemistry Departments(2)
Benha Faculty of Medicine - Zagazig University
and Pharmacology department (3)- Ain Shams Faculty of Medicine, Egypt
* To whom correspondance should be addressed : Diaa El-Mowafi, MD, 4 Ghazza st., El-Hossania, El-Mansoura 35111, Egypt. Fax + 2 050 332771
ABSTRACT
Thirty five hyperprolactinemic women were included in this study. They were attending Benha University Hospitals with different clinical manifestations such as primary and secondary infertility, secondary amenorrhea, oligomenorrhea, pre-menstrual tension syndrome and hirsutism. Eighteen patients had clinically manifested galactorrhea. Sixteen of our patients stopped oral dopamine agonist therapy since at least two months because of its side effects. Our patients were divided into two groups. Each woman in the first group was given one tablet (2.5 mg) of bromocriptine at night by vaginal route for three months , while each woman in the second group was given one tablet (0.2 mg) of lysuride each night by the same route and for the same duration. Serum prolactin was assayed for each case before , two weeks and three months after, starting therapy. A highly significant decline in serum prolactin levels (P < 0.0005) was achieved after two weeks of therapy on both vaginal bromocriptine (53.9% improvement) & vaginal lysuride (53.8% improvement). After three months, thirty patients reached a normoprolactinemic level while five patients, three on bromocriptine and two on lysuride, did not respond to the dose given and doubling the dose was not effective. Also, we found no significant difference between both drugs as they had the same effect on serum prolactin. All the clinical manifestations were relieved or improved including galactorrhea, but adjuvant therapy was needed in eleven patients with infertility, given adjuvant ovulatory drugs, three patients with hirsutism and one patient with secondary amenorrhea. All patients who discontinued the oral therapy because of its side effects did not report any complaint , while on vaginal route the biochemical and clinical response promotes the use of vaginal route as an alternative to the oral one for dopamine agonists therapy.
You can read the entire report at this link.
